Myth emati CS Christos H. Papadimitriou UC Berkeley : christos.
Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon....
-
Upload
victor-lewis -
Category
Documents
-
view
221 -
download
3
Transcript of Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon....
![Page 1: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/1.jpg)
Dr. Christos Toumpanakis MD PhD FRCPConsultant in Gastroenterology/Neuroendocrine Tumours
Hon. Senior Lecturer University College of LondonNeuroendocrine Tumour Unit - ENETS Centre of Excellence
ROYAL FREE HOSPITAL, London,UK
Carcinoid Heart Disease (CHD)
NET MASTERCLASS
What’s new in 2015: an interactive workshop
![Page 2: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/2.jpg)
Carcinoid Syndrome
MIDGUT NETs, OVARIAN NETs, BRONCHIAL NETs
Flushing, diarrhoea, bronchospasm, Carcinoid Heart Disease
• 30 – 40 % of patients with liver metastases • 5% of patients with carcinoid syndrome do not have liver metastases
“Carcinoid crisis” Severe symptoms of carcinoid syndrome + hypotension during
procedures that involve GA, as well as in TAE, and when the patient is on inotropes
![Page 3: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/3.jpg)
Carcinoid Heart Disease
•May develop in 30-50% of patients, with carcinoid syndrome (midgut NETs with hepatic or retro-peritoneal metastases, ovarian NETs and bronchial NETs).
•It represents the development of fibrotic plaques on the heart valves.
•It DOES NOT mean development of myocardial metastases.
•Its development is associated with 30 – 50% reduction in the expected survival of those patients.
Battacharyya S , Toumpanakis C et al, AJC 2008
![Page 4: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/4.jpg)
How CHD develops?• It is mediated by vasoactive substances secreted by the NETs cells:
– 5 hydroxytryptamine (5-HT, serotonin)– Prostaglandins – Histamine– Bradykinin– Substances with fibroblast proliferative properties
• Tachykinins: substance P, neurokinin A, neuropeptide K
• Transforming growth factor β
Fox DJ & Khattar RS. Heart 2004;90:1224-8.Bernheim AM et al, Progress in Cardiovascular Diseases, 2007; 49(6): 439-451.
Deposition of Endocardial
Plaques Composed of:
• MyofibroblastsMyofibroblasts• Smooth muscle cellsSmooth muscle cells
• Deposits of ECMDeposits of ECM (including collagen &
myxoid ground substance)
![Page 5: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/5.jpg)
The Pathways Responsible for the The Pathways Responsible for the Development of CHDDevelopment of CHD
Are still uncertain. Are still uncertain.
The disease is likely to be multifactorial.The disease is likely to be multifactorial.
SEROTONINSEROTONIN
is a major player and is considered to be a major initiator of the is a major player and is considered to be a major initiator of the fibrotic process, by targeting the fibrotic process, by targeting the 5-HT2B receptor.
R. Dobson et al., International Journal of Cardiology 2014; 173: 29-32.Gustafsson BI et al, International Journal of Cardiology 2008; 129: 318-324.
![Page 6: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/6.jpg)
Endocardial deposits of Endocardial deposits of fibrous tissuefibrous tissue
• occur primarily on the downstream side of the valve leaflets (on the ventricular aspect of the tricuspid valve and the pulmonary arterial side of the pulmonary valve) - preferentially right-sided lesions.– the lungs filter the vasoactive peptides, inactivating them in the
pulmonary circulation before they reach the left atrium
Left-sided valvular pathology (5-10%) - seen only in patients with bronchial carcinoid or patent foramen ovale or in those with poorly controlled, severe carcinoid syndrome that overwhelms the pulmonary degradative capacity.
Palaniswamy C et al., Cardiol Rev 2012;20:167-76.Gustafsson BI et al., Int J Cardiol 2008;129(3):318-24.
![Page 7: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/7.jpg)
• ““Carcinoid Plaque” Carcinoid Plaque” - composed of smooth muscle cells & myofibroblasts forming a white fibrous layer lining on the endocardial surface of cardiac valves, superficial to normal valve.
Bhattacharyya S et al. Circ Cardiovasc Imaging. 2010;3:103-111.
![Page 8: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/8.jpg)
• The disease is characterized by retraction & fixation of predominantly the right-sided valve leaflets, leading to a combination of valvular regurgitation & stenosis, which ultimately can progress to right heart failure.A. Dilated right heart, with thickened, retracted tricuspid valve leafletsB. Colour flow Doppler revealing severe jet of TR filling a dilated right
atrium.C. Continuous wave Doppler showing dense jet of TR.
Bernheim AM et al., Prog Cardiovasc Dis 2007;49(6):439-51.
![Page 9: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/9.jpg)
Clinical Features of CHDClinical Features of CHDClinical Features of CHDClinical Features of CHD
• Asymptomatic period - variable• Dyspnea, fatigue• Ascites and peripheral edema
- Cardiac
- Hepatic
- Nutritional
- Combination
![Page 10: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/10.jpg)
NET Biomarkers for screening / diagnosis
A) 24h urine 5-HIAA levels Significantly higher in patients with CHD. Patients with
CHD have on average, 2 to 4-fold higher values of serum serotonin, and platelets serotonin.
Low specificity.
B) Chromogranin-A (CgA) Sensitivity of CgA to predict severe CHD was 100%, but
specificity was only 30%. A level of 784mcg/L resulted in specificity of 75% and
sensitivity of 73%.
No CHD CHD
5-HIAA
Lundin et al, Circulation 1988Zuetenhorst et al, Cancer, 2003Korse et al, J Clin Oncol 2009
![Page 11: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/11.jpg)
NET biomarkers for prediction of development and / or progression of CHD
• Development and progression of CHD were linked to 5-HIAA levels.• 5-HIAA > 300 μmol/L is independent predictor for development and
progression of CHD (2-3 fold increase in risk). Multivariate model, in a prospective study of 252 patients.
• No significant value was noted for Chromogranin-A.
23 patients, 8 had / developed CHD 71 patients
Denney et al, J Am Coll Cardiol 1998Moller et al, NEJM 2003Bhattacharyya et al, Am J cardiol 2011
![Page 12: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/12.jpg)
Natriuretic peptides for screening / diagnosis of CHD
Median NT pro- BNP was significantly higher. Cut-off level : 260 pg/ml, sensitivity 92% & specificity 91%.• Negative and positive predictive values : 0.98 & 0.71 respectively. • Good correlation with CHD ECHO score and functional NYHA class.
NT pro-BNP
ANP
CHD
No CHD
No CHD
CHD
NT pro-BNP
ANP levels were higher in CHD, but no statistically significant.
Zuetenhorst et al, Br J Cancer, 2004Bhattacharyya et al, Am J Cardiol 2008
200 pts were screened, 39 had CHD.
![Page 13: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/13.jpg)
NT pro-BNP as a predictor of survival
• Worse survival in raised levels.• Patients with raised NT proBNP and CgA levels have
a 16% survival probability in 5 years.
Zuetenhorst et al, Br J Cancer, 2004 Korse et al, J Clin Oncol 2009
![Page 14: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/14.jpg)
Central role of c. ECHO for diagnosis• The ECHO spectrum is wide.
• Patients with diffuse thickening of valve leaflets or isolated thickening of a single valve leaflet without significant reduction in leaflet mobility or the development of valvular regurgitation may represent the early stages of carcinoid heart
disease.
• Advanced techniques such as 3D TTE or 3D TEE are helpful in identifying and assessing valve pathology, particularly in the pulmonary and tricuspid valves, because all leaflets may not be visualized on 2D echocardiography.
S. Bhattacharyya et al. Circ Cardiovasc Imaging. 2010
![Page 15: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/15.jpg)
• CMR can be a valuable adjunct where echocardiographic windows
are poor or structures such as the pulmonary valve are difficult to visualize.
• Morphological features of severe carcinoid heart disease can be delineated with assessment of valvular regurgitation, stenosis, and quantification of ventricular volumes.
• CMR enables measurement of size of metastases and is able to offer information regarding extension into extracardiac structures, which is not available on echocardiographic techniques.
Complementary role of cardiac MRI
S. Bhattacharyya et al. Circ Cardiovasc Imaging. 2010
![Page 16: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/16.jpg)
- Assessment of cardiac valves and RV function
- Pre-surgical assessment of coronary arteries
- Assessment of myocardial metastases and their relationship with affected cardiac valves
O.Lazoura presentation, 1st International CHD Symposium, London, 09/2014
Complementary role of CT
![Page 17: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/17.jpg)
Medical Management of CHDMedical Management of CHDMedical Management of CHDMedical Management of CHD
• Watchful waiting for symptoms
• Diuretics for edema – loop or thiazide- May reduce cardiac output
- Fatigue may worsen
• Limited alternative medical options- Digoxin or ACE
Bernheim AM, Connolly HM, Pellikka PA.
Curr Treat Options Cardiovasc Med. 2007
![Page 18: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/18.jpg)
Surgical management of severe CHDSurgical management of severe CHDSurgical management of severe CHDSurgical management of severe CHD
Indications: Individualized
– Symptomatic right heart failure
– Fatigue, dyspnoea oedema, ascites
– Progressive RV enlargement /
dysfunction
– Prior to hepatic surgery
Will valve surgery with inherent risks (mortality 10-25%) result in symptomatic improvement and survival benefit?
Askew JW, Connolly HM.Curr Treat Options Cardiovasc Med. 2013
![Page 19: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/19.jpg)
Functional Improvement following valve surgery for CHD
Significant functional improvement after surgery.
Erasmus University Medical Centre, Rotterdam, The Netherlands EJCTS 2012
![Page 20: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/20.jpg)
0
2 0
4 0
6 0
8 0
1 0 0
0 1 2 3 4 5
SurvivalSurvival (%)(%)
YearsYears
26 Surgical Pt26 Surgical Pt
40 Medical Pt40 Medical Pt
Survival of Patients with Symptomatic Carcinoid Heart Disease
Connolly et al; JACC 1995Connolly et al; JACC 1995
Surgical RxSurgical Rx compared withcompared withhistorical medical controls historical medical controls
![Page 21: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/21.jpg)
Timing of OperationTiming of OperationTiming of OperationTiming of Operation
Prosthesis Prosthesis & Surgical& Surgical
RisksRisks
Progressive Progressive DebilityDebility
![Page 22: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/22.jpg)
• More controversial.
• No large series have compared the choice of valve prosthesis. • Biological valves are usually preferred because:
- They have an acceptable lifespan.- Somatostatin analogues and other antitumour therapies may theoretically
protect the valve from deposition of further carcinoid plaques.- They do not require anticoagulation and consequently lower the risk of
bleeding in patients with hepatic dysfunction and also reduce the risk of valve thrombosis (mechanical valve thrombosis is 4% per year).
SURGICAL MANAGEMENT of CHDChoice of Valve Prosthesis
Raja SG et al, Future Cardiol. 2010
![Page 23: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/23.jpg)
Non – surgical, interventional options
• Percutaneous catheter-based interventions clearly improve the therapeutic options in CHD by minimizing invasiveness, avoiding general anesthesia and allowing staged procedures.
• Feasible mainly for aortic valve, potentially for pulmonary valve and closure of PFO.
• Not suitable for mitral valve.• Not suitable for tricuspid valve. However, heterotopic single or dual caval
valve implantation, for severe TR seems feasible and safe..
![Page 24: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/24.jpg)
Carcinoid syndrome Resistant to SSTA
No radiological progression
Excludeother
causes
• Optimize SSTs• Add interferon
• Clinical trials (Telotristat Etiprate)• Debulking surgery
Radiological progression
• PRRT
• ? Everolimus PredominantlyLiver diseaseTAERFA? SIRT
![Page 25: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/25.jpg)
Take Home Messages• CHD may develop in 30-50% of patients, with carcinoid syndrome and its
development may decrease survival.
• Aggressive carcinoid syndrome treatment may prevent the development and progression of CHD.
• NT pro-BNP seems to be a good screening biomarker.
• Cardiac ECHO remains the diagnostic modality of choice.
• Limited medical therapeutic options.
• It is important to identify the “right” time for valve replacement.
• Advances in surgical treatment improved survival.
• Percutaneous catheter-based interventions seem to be promising alternatives in poor surgical candidates.
• Experienced multidisciplinary team required for state-of-the-art management.
![Page 26: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/26.jpg)
1st International Symposium for Carcinoid Heart Disease – London 4/9/2014
• 89 delegates from 10 different countries UK, US, Germany, France,
Sweden, Norway, Denmark, Netherlands, Ireland, Israel
• 36 : 40% NET physicians• 53 : 60% Cardiologists
(Consultants, Trainees, Technicians)
![Page 27: Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine.](https://reader035.fdocuments.us/reader035/viewer/2022062407/56649e385503460f94b288f0/html5/thumbnails/27.jpg)
Thank you very much